Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Apalutamide in Japanese mCRPC Patients
NCT02162836Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2014
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Dose Limiting Toxicity. Started Jun 2014; status: completed.
02
Drugs
apalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02162836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162836.